Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $7.73B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2025 ·
Decision snapshot: ALKS stock price vs BUD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BUD's multiple
Needs BUD P/E.
Implied fair value · at ALKS's multiple
Needs ALKS P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALKS FY 2025 (ended Dec 31, 2025) · BUD FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 5.19x · EV / EBITDA 23.76x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Alkermes plc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Anheuser-Busch InBev SA/NV · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.17x
—
Net debt / EBITDA
Leverage against operating earnings
-0.22x
—
Cash and equivalents
Liquid reserves on the balance sheet
$388.57M
$11.64B
Total debt
Interest-bearing obligations outstanding
$317.13M
—
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
ALKS vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
ALKS vs SUPN
Amneal Pharmaceuticals, Inc.
ALKS vs AMRX
MOLSON COORS BEVERAGE CO
ALKS vs TAP
BOSTON BEER CO INC
ALKS vs SAM
CONSTELLATION BRANDS, INC.
ALKS vs STZ
Celsius Holdings, Inc.
ALKS vs CELH
Tilray Brands, Inc.
ALKS vs TLRY
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
